Authors
Earl, HVallier, A
Dunn, J
Loi, S
Ogburn, E
McAdam, K
Hughes-Davies, L
Harnett, A
Abraham, J
Wardley, Andrew M
Cameron, D
Miles, D
Gounaris, I
Plummer, C
Hiller, L
Affiliation
Department of Oncology, University of Cambridge, (Box 193-R4) Addenbrooke's Hospital, Hills Road, Cambridge CB2 0QQIssue Date
2016-12-06
Metadata
Show full item recordAbstract
We report cardiac events in the Persephone trial which compares 6-12 months of adjuvant trastuzumab in women with confirmed HER2-positive, early-stage breast cancer.Citation
Trastuzumab-associated cardiac events in the Persephone trial. 2016, 115 (12):1462-1470 Br. J. CancerJournal
British Journal of CancerDOI
10.1038/bjc.2016.357PubMed ID
27875516Type
ArticleLanguage
enISSN
1532-1827ae974a485f413a2113503eed53cd6c53
10.1038/bjc.2016.357
Scopus Count
Collections
Related articles
- Cardiac toxicity events in the PHARE trial, an adjuvant trastuzumab randomised phase III study.
- Authors: Pivot X, Suter T, Nabholtz JM, Pierga JY, Espie M, Lortholary A, Khayat D, Pauporte I, Romieu G, Kramar A, Fumoleau P
- Issue date: 2015 Sep
- Cardiotoxicity and Cardiac Monitoring During Adjuvant Trastuzumab in Daily Dutch Practice: A Study of the Southeast Netherlands Breast Cancer Consortium.
- Authors: Seferina SC, de Boer M, Derksen MW, van den Berkmortel F, van Kampen RJ, van de Wouw AJ, Joore M, Peer PG, Voogd AC, Tjan-Heijnen VC
- Issue date: 2016 May
- 6 versus 12 months of adjuvant trastuzumab for HER2-positive early breast cancer (PERSEPHONE): 4-year disease-free survival results of a randomised phase 3 non-inferiority trial.
- Authors: Earl HM, Hiller L, Vallier AL, Loi S, McAdam K, Hughes-Davies L, Harnett AN, Ah-See ML, Simcock R, Rea D, Raj S, Woodings P, Harries M, Howe D, Raynes K, Higgins HB, Wilcox M, Plummer C, Mansi J, Gounaris I, Mahler-Araujo B, Provenzano E, Chhabra A, Abraham JE, Caldas C, Hall PS, McCabe C, Hulme C, Miles D, Wardley AM, Cameron DA, Dunn JA, PERSEPHONE Steering Committee and Trial Investigators.
- Issue date: 2019 Jun 29
- 6 months versus 12 months of adjuvant trastuzumab for patients with HER2-positive early breast cancer (PHARE): a randomised phase 3 trial.
- Authors: Pivot X, Romieu G, Debled M, Pierga JY, Kerbrat P, Bachelot T, Lortholary A, Espié M, Fumoleau P, Serin D, Jacquin JP, Jouannaud C, Rios M, Abadie-Lacourtoisie S, Tubiana-Mathieu N, Cany L, Catala S, Khayat D, Pauporté I, Kramar A, PHARE trial investigators.
- Issue date: 2013 Jul
- A Prospective Cohort Study on Cardiotoxicity of Adjuvant Trastuzumab Therapy in Breast Cancer Patients.
- Authors: Matos E, Jug B, Blagus R, Zakotnik B
- Issue date: 2016 Jul